2,3-二氯-1,5-二氮杂萘 | 89276-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2,3-二氯-1,5-二氮杂萘
• 英文名称: 2,3-dichloro-1,5-naphthyridine
• CAS: 89276-19-7
• 化学式: C₈H₄Cl₂N₂
• 分子量: 199.039
• InChiKey: ZDSOWHAAHXDGMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-二氯-1,5-二氮杂萘 、 N-Boc-哌嗪 在 2-双环己基膦-2',6'-二甲氧基联苯 、 palladium diacetate 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 以21%的产率得到tert-butyl 4-(3-chloro-1,5-naphthyridin-2-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS
  [FR] INHIBITEURS DE POMPE D'EFFLUX DE BACTÉRIES À GRAM NÉGATIF

  摘要：

  The present invention concerns novel Gram-negative bacteria efflux pump inhibitors. It further relates to the use of Gram-negative bacteria efflux pump inhibitors to prevent and/or treat antibiotic resistance by potentiating the activity of antibiotics. Infections by multidrug resistant (MDR) Gram-negative bacteria are a major threat to global healthcare. The inventors have discovered a novel class of Resistance Nodulation cell Division-efflux pump inhibitors. The inventors tested the effects of these inhibitors on growth inhibition of different bacteria as well as their impact on the boosting of antibiotic activity in different bacteria. Particularly, the inventors tested the effects of these inhibitors on E. coli, A. baumannii, K. pneumoniae and P. aeruginosa.

  公开号：

  WO2023002011A1
• 作为产物：
  描述：

  3-硝基-1,5-萘啶-2(1H)-酮 在 五氯化磷 、 三氯氧磷 作用下， 反应 2.5h， 生成 2-氯-3-硝基-1,5-萘啶 、 2,3-二氯-1,5-二氮杂萘
  参考文献：
  名称：

  Wozniak, M.; Plas, H. C. van der; Tomula, M., Recueil des Travaux Chimiques des Pays-Bas, 1983, vol. 102, p. 511 - 513

  摘要：

  DOI：

文献信息

• WOZNIAK, M.;PLAS, H. C.;TOMULA, M.;VELDHUIZEN, A., REC. TRAV. CHIM. PAYS-BAS, 1983, 102, N 12, 511-513
  作者：WOZNIAK, M.、PLAS, H. C.、TOMULA, M.、VELDHUIZEN, A.

  DOI：——

  日期：——
• Wozniak, M.; Plas, H. C. van der; Tomula, M., Recueil des Travaux Chimiques des Pays-Bas, 1983, vol. 102, p. 511 - 513
  作者：Wozniak, M.、Plas, H. C. van der、Tomula, M.、Veldhuizen, A. van

  DOI：——

  日期：——
• [EN] GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS<br/>[FR] INHIBITEURS DE POMPE D'EFFLUX DE BACTÉRIES À GRAM NÉGATIF
  申请人：[en]INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：WO2023002011A1

  公开（公告）日：2023-01-26

  The present invention concerns novel Gram-negative bacteria efflux pump inhibitors. It further relates to the use of Gram-negative bacteria efflux pump inhibitors to prevent and/or treat antibiotic resistance by potentiating the activity of antibiotics. Infections by multidrug resistant (MDR) Gram-negative bacteria are a major threat to global healthcare. The inventors have discovered a novel class of Resistance Nodulation cell Division-efflux pump inhibitors. The inventors tested the effects of these inhibitors on growth inhibition of different bacteria as well as their impact on the boosting of antibiotic activity in different bacteria. Particularly, the inventors tested the effects of these inhibitors on E. coli, A. baumannii, K. pneumoniae and P. aeruginosa.